LGH447
Total Payments
$227,867
Transactions
10
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $28,075 | 3 | 0 |
| 2018 | $115,184 | 4 | 0 |
| 2017 | $84,608 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $227,867 | 10 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I MULTICENTER OPEN LABEL STUDY OF ORAL LGH447 INPATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH RISK MYELODYSPLASTIC SYNDROME | Novartis Pharmaceuticals Corporation | $176,287 | 0 |
| A PATIENT AND INVESTIGATOR BLINDED RANDOMIZED PLACEBO CONTROLLED STUDY OF LLG783 IN PATIENTS WITH PERIPHERAL ARTERY DISEASE PAD AND INTERMITTENT CLAUDICATION | Novartis Pharmaceuticals Corporation | $27,515 | 0 |
| A MULTI CENTER OPEN LABEL DOSE ESCALATION PHASE 1 STUDY OF ORAL LGH447 IN PATIENTS WITH RELAPSED AND OR REFRACTORY MULTIPLE MYELOMA | Novartis Pharmaceuticals Corporation | $24,065 | 0 |
Top Doctors Receiving Payments for LGH447
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Ann Arbor, MI | $227,867 | 10 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $227,867
Product Information
- Type Drug
- Total Payments $227,867
- Total Doctors 0
- Transactions 10
About LGH447
LGH447 is a drug associated with $227,867 in payments to 0 healthcare providers, recorded across 10 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2019. In 2019, $28,075 was paid across 3 transactions to 0 doctors.
The most common payment nature for LGH447 is "Unspecified" ($227,867, 100.0% of total).
LGH447 is associated with 3 research studies, including "A PHASE I MULTICENTER OPEN LABEL STUDY OF ORAL LGH447 INPATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH RISK MYELODYSPLASTIC SYNDROME" ($176,287).